Open AccessPreexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception
Author(s) -
Renee Heffron,
Nelly Mugo,
Edwin Were,
James Kiarie,
Elizabeth A. Bukusi,
Andrew Mujugira,
Lisa M. Frenkel,
Deborah Donnell,
Allan Ronald,
Connie Celum,
Jared M. Baeten
Publication year - 2014
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000493
Subject(s) - medroxyprogesterone acetate , hormonal contraception , medicine , serodiscordant , gynecology , pre exposure prophylaxis , obstetrics , family planning , medroxyprogesterone , population , vaginal microbicide , emtricitabine , human immunodeficiency virus (hiv) , microbicides for sexually transmitted diseases , viral load , estrogen , family medicine , syphilis , antiretroviral therapy , research methodology , health services , men who have sex with men , environmental health
To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA.